Chronic Spontaneous Urticaria

IL-4Rα blocker stapokibart cleared chronic spontaneous urticaria and improved quality of life after omalizumab failure in a 44-year-old female patient.

The review emphasizes that psychological stress can influence inflammatory pathways involved in CSU, potentially worsening disease activity.

In a pilot study, autologous IgG injections show early, lasting symptom and quality-of-life gains in antihistamine-resistant chronic spontaneous urticaria (CSU).

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

A retrospective study of 199 CSU patients found that elevated baseline D-dimer was the only independent predictor of high-dose omalizumab requirement after multivariate adjustment.

The biologic is the first of its kind approved for young children with antihistamine-refractory CSU, expanding an existing indication that previously covered adults and adolescents.

Take today's poll and explore real-world VHA data showing delayed, low biologic use in chronic spontaneous urticaria, alongside rising ER, inpatient, and outpatient visits after diagnosis.

A rare case shows HAE with chronic spontaneous urticaria; non-itchy facial swelling despite omalizumab signals C4 and C1-INH testing.

Two oral BTK inhibitors and two injectable biologics demonstrated superior efficacy over placebo in a systematic review of 16 CSU trials.

A study shows physician counseling boosts safe adherence and curbs misinformation-driven decisions, as pregnant women often stop skin treatments and experience worsened symptoms.

Omar Noor, MD, shares pearls on type 2 inflammation, including dupilumab insights for atopic dermatitis, prurigo nodularis, and CSU at Horizons in Advanced Practice.

Nicholas Brownstone, MD, and other experts spotlighted cytokine hubs at the 2026 Winter Clinical Miami conference, linking chronic spontaneous urticaria and psoriasis/psoriatic arthritis to smarter targeted treatment choices.

Barzolvolimab is a humanized monoclonal antibody that inhibits the KIT receptor, aiming to reduce mast cell survival and activity in chronic spontaneous urticaria.

Novartis reports RemIND phase 3 success and submits a supplemental New Drug Application to the FDA for symptomatic dermographism.

Septerna to share phase 1 SEP-631 results at AAAAI, targeting MRGPRX2 to curb mast cell flares and broaden options for refractory CSU.

Review identifies clinical and lab predictors of early antihistamines CSU and omalizumab CSU response, guiding personalized treatment.

In omalizumab-resistant chronic spontaneous urticaria (CSU), tofacitinib rapidly calmed symptoms, but relapses varied.

Clinicians assess chronic urticaria prevalence and impact, revealing gaps in understanding and treatment that affect patient care and outcomes.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

CSU significantly impacts family quality of life, revealing the need for comprehensive care and support for both patients and their caregivers.

Jasper Therapeutics reveals promising briquilimab data, showcasing rapid disease control and safety in chronic spontaneous urticaria and chronic inducible urticaria.

Discover the latest advancements in CSU treatment, including new therapies and evolving management strategies for better patient outcomes.

A mother shares her personal journey with her daughter's chronic spontaneous urticaria, highlighting the emotional and treatment challenges faced by families.

A study reveals stress coping strategies and eosinophil levels impact CU in adolescents, highlighting the need for integrated psychological support.

Early-phase development introduces a potential first-in-class oral approach targeting type 2 inflammation relevant to dermatologic diseases.